Mode
Text Size
Log in / Sign up

GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysis

GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysis
Photo by Navy Medicine / Unsplash
Key Takeaway
Note: Observational case report analysis suggests an association between GLP-1RAs and lower respiratory risk.

This study developed a textual time-series corpus from 136 PubMed Open Access single-patient case reports involving glucagon-like peptide-1 receptor agonists (GLP-1RAs). The primary aim was to evaluate automated large language model (LLM) timeline extraction from these reports. The best-performing LLM (GPT5) achieved high event coverage (0.871) and reliable temporal sequencing (0.843).

Using the extracted data, a time-to-event analysis suggested an association between GLP-1RA use and a lower risk of respiratory sequelae compared to non-users. The reported hazard ratio was 0.259, with a p-value of less than 0.05. Absolute event numbers were not reported. No safety, tolerability, or adverse event data from the case reports were provided in the analysis.

Key limitations stem from the study's design. The analysis is based entirely on single-patient case reports, which are inherently observational and subject to reporting bias. The population size is small, and the 'non-user' comparator group is not well-defined. The primary outcome of the underlying reports was not specified, and follow-up duration was not reported. Funding sources and author conflicts of interest were also not reported.

For clinical practice, this analysis generates a hypothesis of an association but does not establish causality. The finding of a lower risk of respiratory sequelae is preliminary and derived from a limited, retrospective data source. Clinicians should interpret this result with caution and await evidence from controlled, prospective studies before considering any clinical implications.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Type 2 diabetes case reports describe complex clinical courses, but their timelines are often expressed in language that is difficult to reuse in longitudinal modeling. To address this gap, we developed a textual time-series corpus of 136 PubMed Open Access single-patient case reports involving glucagon-like peptide 1 receptor agonists, with clinical events associated with their most probable reference times. We evaluated automated LLM timeline extraction against gold-standard timelines annotated by clinical domain experts, assessing how well systems recovered clinical events and their timings. The best-performing LLM produced high event coverage (GPT5; 0.871) and reliable temporal sequencing across symptoms (GPT5; 0.843), diagnoses, treatments, laboratory tests, and outcomes. As a downstream demonstration, time-to-event analyses in diabetes suggested lower risk of respiratory sequelae among GLP-1 users versus non-users (HR=0.259, p<0.05), consistent with prior reports of improved respiratory outcomes. Temporal annotations and code will be released upon acceptance.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.